Cost-effectiveness analysis of paclitaxel micellar for treatment of first relapse platinum sensitive ovarian cancer

Previous PostEstimating the true cost of weight-based chemotherapy
Next PostImpact of Brexit-induced changes to regulatory approval on UK access to medicines